Overview
Case summary
This patent infringement case involves U.S. Patent No. 250,247 granted to John Holliday in 1881 for 'the sulpho-conjugated compound of rosaniline' as a new article of manufacture, used as a coloring compound (acid magenta). The patent was assigned to Read Holliday & Sons, who sued defendants Schulze-Berge et al. for producing 'New Acid Magenta' from C22 (trimethyl para rosaniline). The court found the patent valid based on prior litigation. Defendants argued non-infringement because C22 was not isolated as a chemical individual until 1882, after the patent date, and that certain tests showed different results. The court held that C22 was known in the art before the patent through French patents and research, and is a homologue of the patented rosanilines (C19, C20, C21). Applying the doctrine of equivalents, the court found infringement because C22 would have been known to a skilled chemist, its substitution involved no alteration, and it produced the same product using the same process. The court distinguished Matheson v. Campbell, where the patent had an uncertain general formula. The court entered a decree for injunction and accounting.
Abstract
This patent infringement case concerns a patent for a sulpho-conjugated compound of rosaniline used as a coloring compound, assigned to the patentee's company, which sued defendants for producing a similar compound from a homologue known in prior art. The court upheld the patent's validity, applied the doctrine of equivalents to find infringement despite chemical differences, and distinguished prior case law involving uncertain formulas. A decree was entered for an injunction and accounting.
Opinion of the court
opinionTOWNSEND, District Judge
- Patent valid based on prior adjudications
- Defendants' product C22 is equivalent to patented rosanilines
- Doctrine of equivalents applies to protect patentee against ingredients known at patent date
- Patent covers discovered, described elements even if not isolated until later
- Distinction between primary and secondary inventions affects scope of equivalents
Jurisdiction
not challenged- Suit filed in Circuit Court, S.D. New York
- Involves federal patent law
Procedural posture
- Validity of patent
- Infringement
- Scope of patent claim
- Doctrine of equivalents
Legal categories
Case record
Issues & holdings
De novo for legal issues of patent scope and infringement
Defendants' product is equivalent and covered by patent under doctrine of equivalents
Issue preserved for review
De novo
C22 was known in art before patent and is homologue covered by patent
Issue preserved for review
De novo
Doctrine applies where new ingredient would have been known to skilled chemist and substitution involves no alteration
Issue preserved for review
Holdings of the court
Standards of review
- Patent infringement and scope — de novo Legal issues of patent interpretation and infringement reviewed de novo
Timeline
French patent of Coupier and Holliday's French patent No. 71,114 indicate knowledge of rosaniline class including C22
Shows C22 was known in art before Holliday's 1881 patent
Patent No. 250,247 granted to John Holliday for sulpho-conjugated compound of rosaniline
Patent in suit granted
C22 first isolated and described as chemical individual by Rosenstiel and Gerber
Defendants argue C22 not isolated until after patent date
Court finds infringement, orders injunction and accounting
Outcome: Injunction granted and accounting ordered
Final decision in current case
Facts & evidence
Key facts
7 facts- Patent No. 250,247 granted November 29, 1881 to John Holliday, assigned to complainant
- Claim 1: 'The sulpho-conjugated compound of rosaniline, possessing the properties specified, as a new article of manufacture'
- Defendants produce 'New Acid Magenta' from triamido triortho toiyl carbinol (C22)
- C22 is a homologue of rosanilines C19, C20, C21 covered by patent
- Defendants use same process as patent to produce equivalent product
- C22 was known before patent date through French patent of Coupier (1866) and Holliday's French patent
- C22 not isolated as chemical individual until 1882, after patent grant
Procedural history
3 steps- Prior litigation: Holliday v. Pickhardt (12 Fed. 147) - preliminary injunction considered by Judge Blatchford
- Prior litigation: Holliday v. Pickhardt (29 Fed. 853) - final hearing by Judge Wallace sustained patent validity
- Current suit against Schulze-Berge et al. for infringement
Evidence in the record
- Defendants' product 'New Acid Magenta'
- Complainant's acid magenta
- Admissions of defendants' experts Woltereek, Homolka, Laubenheimer, and Chandler
- Patent No. 250,247
- French patent of Coupier (1866)
- French patent No. 71,114 to John Holliday (1866)
- Published researches
- Expert name: Defendants' experts · Expertise: Chemistry · Opinion: C22 was known and used before date of patent in suit
- Evidence type: Test results comparing defendants' and complainants' products · Challenge basis: Defendants argued certain tests not specified in patent show different results · Trial court ruling: admitted · Reasoning: Judge Wallace previously found patent tests sufficient to identify product; application to defendants' body shows identity · Challenged on appeal: false · Appellate outcome: not applicable
Objects of relevance
Authorities
Cited authorities (12)
Statutes
- U.S. Patent No. 250,247
Standards & doctrines
- Doctrine of equivalents
- Doctrine of unknown equivalents
- Prima facie case of infringement
Legal principles applied
- Discoverer protected against equivalent ingredients known at patent date
- Patent may cover discovered, described element even if not isolated until later